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DObjective: Factors contributing to postoperative complications include blood loss and a heightened inflamma-
tory response. The objective of this study was to test the hypothesis that aprotinin would decrease perioperative
blood product use, reduce biomarkers of inflammation, and result in improved clinical outcome parameters in
neonates undergoing cardiac operations.
Methods: This was a secondary retrospective analysis of a clinical trial whereby neonates undergoing cardiac
surgery received either aprotinin (n ¼ 34; before May 2008) or tranexamic acid (n ¼ 42; after May 2008).
Perioperative blood product use, clinical course, and measurements of cytokines were compared.
Results: Use of perioperative red blood cells, cryoprecipitate, and platelets was reduced in neonates receiving
aprotinin compared with tranexamic acid (P<.05). Recombinant activated factor VII use (2/34 [6%] vs 18/42
[43%]; P<.001), delayed sternal closure (12/34 [35%] vs 26/42 [62%]; P ¼ .02), and inotropic requirements
at 24 and 36 hours (P<.05) were also reduced in the aprotinin group. Median duration of mechanical ventilation
was reduced compared with tranexamic acid: 2.9 days (interquartile range: 1.7-5.1 days) versus 4.2 days
(2.9-5.2days), P ¼ .04. Production of tumor necrosis factor and interleukin-2 activation were attenuated in the
aprotinin group at 24 hours postoperatively. No differential effects on renal function were seen between agents.
Conclusions:Aprotinin, compared with tranexamic acid, was associated with reduced perioperative blood prod-
uct use, improved early indices of postoperative recovery, and attenuated indices of cytokine activation, without
early adverse effects. These findings suggest that aprotinin may have unique effects in the context of neonatal
cardiac surgery and challenge contentions that antifibrinolytics are equivalent with respect to early postoperative
outcomes. (J Thorac Cardiovasc Surg 2012;143:1069-76)Surgical correction or palliation of most congenital cardiac
defects requires cardiopulmonary bypass (CPB) and antico-
agulation. Abnormalities of the coagulation cascades and
difficulty maintaining hemostasis often persist in the perio-
perative period, requiring administration of blood and
clotting factors. Blood product administration has been
shown to exacerbate the already heightened inflammatory
response that develops after the exposure to CPB and the
related trauma of surgery.1,2 These factors can contribute
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The Journal of Thoracic and Carsyndrome (LCOS), abnormal fluid balance, and increased
need for mechanical and pharmacologic support.3,4
Antifibrinolytics, such as the serine protease inhibitor
aprotinin and the lysine analogs tranexamic acid (TXA)
and aminocaproic acid, have been used to improve hemo-
stasis after CPB. Lysine analogs reversibly bind to the
lysine-binding site on plasminogen to prevent its conversion
into plasmin, a serine protease that degrades fibrin. Aproti-
nin forms reversible enzyme-inhibitor complexes with
plasmin to inhibit fibrinolysis. Unlike the lysine analogs,
aprotinin can inhibit other proteases, such as thrombin
and kallikrein, affording additional hemostatic effects and
potential anti-inflammatory effects.
Aprotinin has been associated with increased morbidity
(specifically renal dysfunction and thrombotic complications)
and mortality in adults undergoing cardiac operations; these
data ultimately resulted in voluntary removal of the drug
from clinical availability in 2008.5,6 The evidence for an
unfavorable risk-benefit ratio for aprotinin has not been dem-
onstrated in the pediatric cardiac population.7-11 In addition
to its antifibrinolytic effects, aprotinin may have anti-
inflammatory and neuroprotective properties.12-14 Whether
these antifibrinolytic agents with different mechanisms of
action and effect result in different postoperative outcomes in
neonatal cardiac surgery has not been examined. Somediovascular Surgery c Volume 143, Number 5 1069
Abbreviations and Acronyms
AKI ¼ acute kidney injury
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
IL ¼ interleukin
IQR ¼ interquartile range
LCOS ¼ low cardiac output syndrome
TNF-a ¼ tumor necrosis factor-alpha
TXA ¼ tranexamic acid
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Dstudies suggest that the lysine analogsmaynotbeas effective in
reducing early postoperative bleeding as aprotinin.9,15
Furthermore, results and interpretation of the aforementioned
studies in adult cardiac surgery patients that linked aprotinin
to significant postoperative complications, as well as their
applicability to pediatric cardiac surgery patients, have
recently been called into question.7,16,17 The primary
objective of this study was to test the hypothesis that
aprotinin would decrease perioperative blood product use
and reduce biomarkers of inflammation, resulting in
improved clinical outcomes in neonates undergoing cardiac
operations.
METHODS
The study involves a secondary analysis of a prospective randomized
controlled trial comparing preoperative glucocorticoid therapy in 76 neo-
nates (ClinicalTrials.gov Identifier NCT00934843).18 During this trial,
aprotinin was withdrawn from clinical use. Aprotinin was used in all pa-
tients except one before May 2008 (n ¼ 34) and no patient after this date
owing to its unavailability. TXAwas used in all patients that did not receive
aprotinin (n ¼ 42). The study was approved by the institutional review
board. Informed written consent was obtained from the parent or legal
guardian of all participants.
Study Population
Patient selection, enrollment, and randomization have been previously
described.18 In brief, all inpatient neonates (30 days of age) scheduled
to undergo cardiac surgery involving CPB from the time period of July
2007 through July 2009 were eligible for this study. Exclusion criteria in-
cluded prematurity (defined as  36 weeks’ gestational age) at the time of
surgery, previous treatment with or contraindication to steroid therapy, or
the preoperative use of mechanical circulatory support or active resuscita-
tion at the timeof proposed randomization. Patientswere randomly assigned
to either preoperative placebo and intraoperative methylprednisolone or
preoperative and intraoperative methylprednisolone.
The present study was dichotomized with respect to the antifibrinolytic
used. The aprotinin dose consisted of both an intravenous and CPB prime
load of 200mg/m2 body surface area (1.43 106 KIU/m2 body surface area)
followed by a continuous infusion of 50mg $m2 $ h1. The dosing regimen
for TXA consisted of both an intravenous and CPB prime load of
100 mg/kg, followed by a 10 mg $ kg1 $ h1 continuous infusion.
Cardiac Surgical Procedure and Postoperative
Protocol
Methylprednisolone at a dose of 30 mg/kg was given about 8 hours be-
fore CPB in 39 (51%) of 76 patients, 16 (47%) of 34 receiving aprotinin1070 The Journal of Thoracic and Cardiovascular Surand 23 (55%) of 42 receiving TXA. In the operating room, general anes-
thesia was attained with narcotics, muscle paralysis, and inhaled anesthetic.
All cardiac operations were performed by 1 of 2 attending surgeons. The
distribution of operations between surgeons remained consistent through-
out the study. The CPB prime included 30 mg/kg of methylprednisolone
in all patients as well as banked, packed red blood cells and fresh frozen
plasma. A heparin-bonded circuit was used for circulatory support. Sys-
temic anticoagulation was achieved with a heparin bolus of 400 units/kg,
with additional doses administered to maintain kaolin-based activated clot-
ting time greater than 500 seconds. Full-flow bypass at mild hypothermia
(32C) or low-flow bypass at deep hypothermia (20C-25C) was used.
Cold blood cardioplegic solution was given at 20-minute intervals during
periods of aortic crossclamping. Deep hypothermic circulatory arrest was
performed at 18C, when necessary. Acid–base management was by
a pH-stat strategy. Conventional and modified ultrafiltration was used in
all cases. Leukocyte depletion filters were not used in any patient. A stan-
dardized approach to blood product administration was used. Platelet and
fibrinogen concentrations were obtained on rewarming. If the fibrinogen
count was less than 100 mg/dL, 1 unit of cryoprecipitate was given. If
the platelet count was less than 100 k/mm3 or bleeding was expected
(eg, Stansel-type anastomosis or arterial switch procedure), platelets
were given at a volume of 10mL/kg. Fresh frozen plasmawas administered
at a volume up to 20 mL/kg if nonsurgical bleeding persisted after prot-
amine administration and correction of these deficiencies. If nonsurgical
bleeding persisted despite these measures (2 doses each of platelets, cryo-
precipitate, and fresh frozen plasma) and careful inspection of the surgical
field, recombinant activated factor VII was considered. Recombinant acti-
vated factor VII, when given, was administered at a dose of 45 to 90 mg/kg
for up to 3 doses after approval by a doctor of pharmacy (W.E.U). Delayed
sternal closure was used in all patients undergoing a Norwood procedure
and in other operations as needed for hemorrhage and/or hemodyamic in-
stability. All patients were managed postoperatively in a dedicated pediat-
ric cardiac intensive care unit (ICU). Typically, milrinone at 0.5 mg $ kg1 $
min1 and dopamine at 5 mg $ kg1 $min1 were initiated before separation
fromCPB and titrated as needed. Titration, addition, and discontinuation of
vasoactivemedications were at the discretion of the cardiac intensivists and
surgeons caring for the patients on the basis of each patient’s physiologic
state and were not driven by strict protocol.Clinical Outcome Measures
The primary outcome measurements were perioperative blood product
and recombinant activated factor VII use through the second postoperative
day. Additional outcome measurements included the incidence of delayed
sternal closure, LCOS, acute kidney injury (AKI), and the inotropic score
over the initial 36 hours postoperatively. The duration of postoperative me-
chanical ventilation, ICU and hospital stays, as well as the 30-day mortal-
ity, were also compared. Patients whose palliation included either
a ventricular or systemic arterial shunt to provide controlled pulmonary
blood flow were compared for shunt thrombosis during the hospitalization.
The inotropic score was calculated by this equation using drug dosages in
micrograms per kilogram per minute (dopamine þ dobutamine)
þ (milrinone 3 10)þ (epinephrine 3 100) and recorded on arrival in the
ICU, 4, 8, 12, 24, and 36 hours postoperatively. The highest score during
this time frame was also recorded. The presence of LCOS was defined us-
ing the same criteria as the PRIMACORP study.19 Specifically, LCOS was
defined by the presence of clinical signs and/or symptoms of low cardiac
output that required one or more of the following interventions: mechanical
circulatory support, the escalation of existing pharmacologic circulatory
support to more than 100% over baseline, or the initiation of new pharma-
cologic circulatory support. Although multiple classification systems for
AKI have been described, none has been shown to predict renal outcomes
in the postoperative pediatric cardiac setting.20 Therefore, a modification of
the Acute Kidney Injury Network criteria was applied.20 Specifically, post-
operative AKI was defined as an increase in serum creatinine above thegery c May 2012
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Dpreoperative level by either an absolute value of more than 0.3 mg/dL or
a 50% increase or greater. Given the frequency of oliguria in neonatal pa-
tients after cardiac surgery, the Acute Kidney Injury Network’s alternative
criteria of urine output below 0.5 mL $ kg1 $ h1 over a 6-hour period was
not applied. Total hospital charges, which encompassed all charges incured
through the entire hospitalization with the exception of physician charges,
were compared between antifibrinolytic groups.
Inflammatory Biomarkers
Selected biomarkers of inflammation were compared between groups
by measuring plasma concentrations of the proinflammatory interleukins
(IL), IL-2, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-a). Whole
blood samples of 1 mL were collected in ethylenediaminetetraacetic acid
tubes preoperatively and 24 hours postoperatively. Plasma was isolated
by centrifugation, decanted into aliquots, and stored at80C until pro-
cessed for immunoassays. Plasma levels of cytokines were determined
by multiplex suspension array using commercially available kits following
the manufacturer’s recommendations (R&D Systems, Minneapolis, Minn).
All samples were measured simultaneously, thereby minimizing interassay
variability. Plasma levels were corrected for hemodilution. Additionally,
serum C-reactive protein concentratons were determined 36 hours
postoperatively.
Data Analysis
Demographic, clinical, and perioperative response variables were com-
pared between the aprotinin and TXA groups with a Wilcoxon rank sum
test for continuous variables and a Pearson c2 or Fisher’s exact test for cat-
egorical variables. With respect to the repeated-measures postoperative
outcome variables such as inotropic score, a repeated-measures analysis
of variance was performed with group and time as predictors, followed
by Bonferroni adjusted pairwise comparisons between groups at each
time point. For analysis of the cytokine outcomes, 2 approaches were
used. First, the values were log10-transformed and then compared by group
using an unpaired t test. Second, the absolute change in relative cytokine
values at 24 hours postoperatively was computed from individual baseline,
preoperative values, and an unpaired t test performed with the null hypoth-
esis that the change was 0. Perioperative and postoperative values are pre-
sented as the mean the standard error of the mean and are also presented
as the median and the interquartile range (IQR). Statistical analyses were
performed with SAS (version 9.1.3; SAS Institute, Inc, Cary, NC).
RESULTS
Preoperative Demographics and Intraoperative
Variables
A total of 76 neonates received either aprotinin (n ¼ 34;
45%) or TXA (n ¼ 42; 55%). Patient demographics, base-
line clinical characteristics, cardiac malformations, and sur-
gical procedures performed were similar between groups
(Table 1). Intraoperative parameters were also similar be-
tween the 2 antifibrinolytic groups, median (IQR); CPB
time was 146 (52) versus 157 (48) minutes (P ¼ .59), and
aortic crossclamp time was 69 (41) versus 72 (41) minutes
(P¼ .4) in the aprotinin and TXA groups, respectively. The
use of deep hypothermic circulatory arrest and the duration
of modified ultrafiltration were also not different between
groups (data not shown).
Postoperative Outcomes: Clinical Variables
Delayed sternal closure was used in 12 (35%) of the 34
patients in the aprotinin group and 26 (62%) of the 42The Journal of Thoracic and Carpatients in the TXA group (P ¼ .02; c2 ¼ 5.32 compared
with aprotinin strategy). Planned delayed sternal closure
with Norwood procedures occurred in a similar percentage
of patients between groups; 8 (24%) of 34 in the aprotinin
group versus 11 (26%) of 42 in the TXA group (P ¼ 1.0).
Excluding patients with a planned delayed sternal closure,
ongoing uncontrolled bleeding was the cited cause of un-
planned delayed sternal closure in 1 (4%) of 26 patients
in the aprotinin group versus 11 (36%) of 31 patients in
the TXA group (P¼ .004). An expected change in inotropic
requirement over time was seen in both groups (Figure 1).
However, inotrope requirement was reduced at 24 and 36
hours postoperatively in the aprotinin group. Additional
postoperative outcomes are shown in Table 2. In neonates
receiving aprotinin, the duration of mechanical ventilation
was reduced compared with TXA. In addition, there was
a trend for a shorter ICU stay in the aprotinin patients. Fluid
balance and indices of renal function at 36 hours postoper-
atively are also shown in Table 2. A trend toward decreased
incidence of AKI at 36 hours postoperatively, with AKI de-
fined as an increase in serum creatinine by an absolute value
of 0.3 mg/dL or more or a 50% increase above baseline,
was seen in the aprotinin group: 6 (18%) of 34 aprotinin
versus 17 (41%) of 42 TXA (P¼ .057). No patient in either
group required dialysis. The incidence of LCOSwas similar
between groups; 14 (41%) of 34 aprotinin versus 18 (43%)
of 42 TXA (P ¼ .88). Overall, 30-day survival was 98.7%.
There was a single death in the aprotinin group, secondary
to gram-negative sepsis 19 days after a central shunt and
pulmonary arterioplasty for tetralogy of Fallot with pulmo-
nary atresia. Partial or complete shunt thrombosis occurred
in 1 (7%) of 15 patients in the aprotinin group who were
palliated with a shunt versus 1 (6%) of 17 such patients
in the TXA group (P¼ 1.0). Thrombosis occurred 50 hours
and 2 hours after the operation in the aprotinin and TXA
patient, respectively.
Inflammatory Biomarkers
Preoperative values of the proinflammatory cytokines
were similar between the groups (P>.05). Composite pre-
operative levels in picograms per milliliter were as follows:
IL-2, 0.8  0.2; IL-6, 41  21; IL-8, 41  7; and TNF-a,
4.1  0.4. Aprotinin administration resulted in an attenu-
ated postoperative inflammatory response (Figure 2). Com-
paring the absolute change at 24 hours postoperatively with
the preoperative levels, in the aprotinin group only IL-8 was
elevated above baseline (P<.05). In contrast, in the TXA
group, IL-2, IL-6, IL-8, and TNF-a were all elevated above
baseline (P< .05). However, the 2 antifibrinolytic groups
were similar in regard to all absolute cytokine values mea-
sured at 24 hours postoperatively (P>.05). Serum C-reac-
tive protein was also similar between groups at 36 hours:
5.0 mg/dL (IQR 3.2) aprotinin versus 5.3 (IQR 3.1) TXA
(P ¼ .51).diovascular Surgery c Volume 143, Number 5 1071
TABLE 1. Preoperative demographics, diagnosis, and procedures in neonatal patients having cardiac surgery, aprotinin or tranexamic acid
strategy
APR (n ¼ 34) TXA (n ¼ 42) P value/operative procedure
Demographics
Male, n (%) 19 (56%) 20 (48%) .47
Prenatal diagnosis, n (%) 16 (47%) 17 (40%) .57
Highest lactate (mmol/L) 4.0  0.8 4.0  0.5 .99
3.1 (1.9) 3.2 (2.3)
Highest creatinine (mg/dL) 0.84  0.03 0.83  0.04 .84
0.90 (0.30) 0.80 (0.20)
Demographics at surgery
Gestational age (wk) 40.1  0.3 39.7  0.2 .59
39.9 (1.4) 39.9 (2.3)
Age (d) 8.5  1.0 8.9  0.9 .59
6.5 (3.0) 7.0 (5.0)
Age  7 d, n (%) 17 (50%) 19 (45%) .68
Weight (kg) 3.2  0.1 3.2  0.1 .74
3.2 (0.6) 3.2 (0.7)
Mechanical ventilation, n (%) 10 (29%) 13 (31%) .92
Inotropic support, n (%) 2 (6%) 3 (7%) .99
Creatinine (mg/dL) 0.54  0.03 0.52  0.03 .61
0.50 (0.10) 0.50 (0.20)
Diagnosis
Corrective procedures 19 (56%) 24 (57%) .90
Aortic arch hypoplasia with VSD 6 4 Aortic arch repair, VSD closure
Tetralogy of Fallot 1 3 Complete repair
TGA  VSD 9 12 Arterial switch  VSD closure
Truncus arteriosis 2 2 Complete repair
Other biventricular repair 1 3
Palliative procedures 15 (44%) 18 (43%) .90
HLHS 6 8 Norwood procedure
Other single-ventricle lesions 8 7 Norwood, mBTS, RV-PA shunt,
pulmonary artery operation
PA with IVS 0 2 RVOT patch, mBTS
Tetralogy of Fallot with PA 1 1 mBTS and pulmonary arterioplasty
Values presented as mean standard error of the mean, median (interquartile range), and number (percent). APR,Aprotinin; TXA, tranexamic acid;VSD, ventricular septal defect;
TGA, transposition of the great arteries;HLHS, hypoplastic left heart syndrome;mBTS,modified Blalock-Taussig shunt; RV-PA, right ventricle–pulmonary artery; PA, pulmonary
atresia; IVS, intact ventricular septum; RVOT, right ventricular outflow tract.
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DPerioperative Blood Product Use and Hospital
Charges
Use of red blood cells, cryoprecipitate, and platelets was
diminished in the group receiving aprotinin, implying im-
proved hemostasis (Figure 3). Similarly, recombinant acti-
vated factor VII was used in 6% (2/34) of the aprotinin
group compared with 43% (18/42) in the TXA group
(P < .0001). Total hospital charges were an average
$218,000  $29,000 aprotinin versus $269,000  $27,000
TXA (P ¼ .004).
DISCUSSION
The unique findings of this study are 3-fold. First, aproti-
nin appeared to be superior to TXA in providing hemostasis
in neonatal cardiac surgery. Second, aprotinin was associ-
ated with improved clinical outcomes, including a lower in-
cidence of delayed sternal closure, reduced inotropic1072 The Journal of Thoracic and Cardiovascular Surrequirement, a shorter duration of mechanical ventilation,
and lower total hospital charges. Third, aprotinin use in ne-
onates was not associated with thrombotic complications or
AKI, as defined by the Acute Kidney Injury Network’s cri-
teria of an increase in serum creatinine by an absolute value
of 0.3 mg/dL or more or a 50% increase over the preoper-
ative level. The results from this study suggest that aprotinin
reduces postoperative bleeding and is associated with
improved early outcomes and decreased cost in neonatal
cardiac surgery when compared with TXA, without detri-
mental outcomes on renal function.
Antifibrinolytic Therapy and Neonatal Cardiac
Surgery
Few studies have explored antifibrinolytic therapy specif-
ically in the neonatal population. Williams and associates21
undertook a randomized placebo-controlled trial ofgery c May 2012
FIGURE 1. Inotropic score after cardiopulmonary bypass. An expected
change in inotropic requirement over time was seen in both groups. There
was a reduced inotropic requirement at 24 and 36 hours postoperatively in
the aprotinin group (*P<.05) compared with aprotinin strategy. Values
presented as mean  standard error of the mean.
TABLE 2. Univariate postoperative outcomes in neonatal patients
having cardiac surgery, aprotinin or tranexamic acid strategy
APR
(n ¼ 34)
TXA
(n ¼ 42)
P
value
Delayed sternal closure, n (%) 12 (35%) 26 (62%) .02
Mechanical ventilation, d 6.1  1.7 6.5  1.2 .04
2.9 (3.4) 4.2 (2.3)
ICU stay, d 11.1  3.4 10.7  1.8 .13
5.9 (4.6) 7.1 (4.3)
Hospital stay, d 22.1  4.3 22.6  2.4 .36
17.5 (14) 18.0 (23.0)
Highest inotropic score 14.0  0.6 15.3  0.6 .14
14.5 (5.5) 15.0 (6.0)
Highest lactate, mmol/L 4.5  0.6 4.6  0.4 .31
3.4 (2.2) 4.1 (2.6)
Mechanical circulatory support, n (%) 2 (6%) 2 (5%) .83
Fluid balance and indices of renal
function
Total fluid in at 36 hours, mL 597  28 568  21 .52
534 (181) 537 (159)
Total urine output at 36 hours, mL 490  34 463  37 .27
500 (250) 404 (300)
Creatinine at 36 hours, mg/dL 0.65  0.05 0.68  0.05 .56
0.55 (0.20) 0.60 (0.30)
Preop to 36-hour postop creatinine
change, mg/dL
0.10  0.05 0.16  0.03 .09
0.10 (0.20) 0.15 (0.30)
Preop to postop creatinine change
 0.3 mg/dL
5 (15%) 13 (31%) .11
Preop to postop creatinine change
 50%
6 (18%) 14 (33%) .20
Values presented as mean  standard error of the mean/median (interquartile range).
APR, Aprotinin; TXA, tranexamic acid; ICU, intensive care unit.
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Daprotinin in neonates. However, the US Food and Drug Ad-
ministration’s concerns over the safety of aprotinin led to
the premature closure of study enrollment. Twenty-six neo-
nates were randomized to aprotinin or placebo. All outcome
variables, other than total amount of blood products trans-
fused in 24 hours, favored aprotinin. However, only the
amount of platelets transfused reached statistical signifi-
cance. Given the premature termination of the study, it
was likely insufficiently powered. Verma and associates22
randomized 24 neonates undergoing the arterial switch op-
eration for transposition of the great arteries to a low-, me-
dium-, or high-dose aprotinin strategy. They reported that
the high-dose regimen was most effective in reducing post-
operative blood loss and red blood cell transfusions and was
without apparent adverse effects.
Despite the paucity of neonatal data, aprotinin adminis-
tration has been demonstrated to improve perioperative
hemostasis in numerous adult and pediatric trials. In
a meta-analysis of 12 studies that enrolled 626 children,
aprotinin reduced the proportion of children who received
blood transfusions during cardiac surgery by 33%.23 Breuer
and colleagues9 compared aprotinin to TXA in 199 children
weighing less than 20 kg and found greater blood-sparing
effects and fewer reexplorations for bleeding in the aproti-
nin group. There were no differences between groups in
postoperative complications or 1-year mortality. They re-
ported a tendency for a higher incidence of seizures in the
TXA group, an interesting finding given recent results in
adults and one that may be dose-related.24 The findings of
the current study lend further support that aprotinin results
in improved postoperative hemostasis, including the vulner-
able neonatal population. The importance of reducing blood
product transfusion cannot be overstated. Although theThe Journal of Thoracic and Caradministration of blood products is now rarely associated
with the transmission of infections, transfusions have
been associated with postoperative infection, morbidity,
mortality, prolonged hospital stay, and increased cost in
adults undergoing coronary revascularization. The general-
ization of these data to pediatrics is limited; however,
emerging data in the pediatric cardiac population are con-
sistent with published information in both children and
adults describing the association of poor outcomes with
blood transfusions.3,4Renal Dysfunction and Antifibrinolytics
Observational data in adults undergoing coronary revas-
cularization suggested aprotinin use was associated with
a doubling in the risk of renal failure necessitating dialysis.5
Several single-institution retrospective analyses have sug-
gested this does not occur in the pediatric population.8,10,11
In a retrospective analysis of 200 neonatal cases evaluating
the safety of aprotinin, Guzzetta and colleagues8 found no
difference between aprotinin recipients and nonreceipients
with respect to postoperative dialysis, thrombosis, ordiovascular Surgery c Volume 143, Number 5 1073
Interleukin-2
Ch
an
ge
 fr
om
 P
re
-O
p 
(pg
/m
L)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Aprotinin TranexamicAcid
+
Interleukin-6
Ch
an
ge
 fr
om
 P
re
-O
p 
(pg
/m
L)
0
20
40
60
80
100
120
140
160
Aprotinin TranexamicAcid
+
Interleukin-8
Ch
an
ge
 fr
om
 P
re
-O
p 
(pg
/m
L)
0
10
20
30
40
50
60
70
Aprotinin TranexamicAcid
+
+
Tumor Necrosis Factor
Ch
an
ge
 fr
om
 P
re
-O
p 
(pg
/m
L)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Aprotinin TranexamicAcid
+
FIGURE 2. Cytokine changes 24 hours postoperatively in neonatal cardiac surgery patients, aprotinin or tranexamic acid (TXA) strategy. Comparing the
absolute change at 24 hours postoperatively to preoperative levels, in the aprotinin group only interleukin 8 (IL-8)was elevated above baseline. In contrast, in
the TXA group IL-2, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-a) were all elevated above baseline (þP<.05) compared with preoperative values.
Values presented as mean  standard error of the mean.
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Din-hospital mortality. They further demonstrated that post-
operative renal dysfunction was predicted by the duration
of CPB and not by aprotinin administration. In the largest
pediatric study, Pasquali and associates7 used the PediatricRed Blood Cells
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stay between aprotinin recipients and nonrecipients. In
a subanalysis of the cohort undergoing reoperation, aproti-
nin recipients had a significantly reduced hospital length of
stay with no difference between groups in incidence of mor-
tality or dialysis. Although this study has the inherent lim-
itations of any observational study using a large database, it
is in general agreement with the results of the current study.
Inflammation and Antifibrinolytics
Much of the perioperativemorbidity that occurs after car-
diac surgery has been attributed to the pathophysiologic
processes resulting from stimulation of the systemic inflam-
matory response, which includes production of proinflam-
matory cytokines, chemokines, complement activation,
activated leukocytes, thrombin, kallikrein and other kinins,
and reactive oxygen and nitrogen species.1,2 Relevant risk
factors, many of which are alleged to result in an increased
inflammatory response in the neonate and young infant,
include the presence of a preinflamed state owing to
cyanosis or other factors, larger degree of exposure to the
artificial CPB circuit, increased shear (higher CPB flow
rates), longer bypass and aortic crossclamp times, and
greater use of cardiotomy suction and resultant blood
trauma. This systemic inflammatory response syndrome
has been postulated to negatively affect postoperative
cardiac function, systemic and pulmonary hemodynamics,
renal function, and immunologic competence, resulting in
greater morbidity. These concerns about the post-CPB in-
flammatory response and its consequences have resulted in
a number of interventions directed at its reduction. Unlike
the lysine analog TXA, aprotinin is a nonspecific serine pro-
tease inhibitor that can inhibit other serine proteases such as
kallikrein, thrombin, and perhaps complement activation,
endowing it with potential and diverse anti-inflammatory
targets.25 The current study demonstrated aprotinin admin-
istration attenuated many (but not all) of the measured com-
ponents of the postoperative inflammatory response.
Whether the improved clinical outcomes were due to re-
duced transfusion, anti-inflammatory effects, or a combina-
tion thereof is yet to be determined.
Limitations
This study exploited the fact that aprotinin was sus-
pended from clinical use midway through a prospective ran-
domized controlled trial of steroid treatment in neonates
undergoing cardiac operations and is therefore limited by
its observational retrospective design. The groups were di-
chotomized with respect to the antifibrinolytic used, with
the aprotinin recipients essentially representing historical
controls. This resulted in a balanced set of patients in
each treatment arm that provided control for a number of
potentially confounding variables. Interestingly, unlike
most studies using historical controls, the contemporaryThe Journal of Thoracic and Cargroup (TXA) did worse. However, caution must be taken
when interpreting the differential effects of blood product
administration inasmuch as these decisions were made in
an unblinded fashion and not driven by strict objective pro-
tocols. In addition, hospital charges were not adjusted for
possible inflation. ICU charges did not change, but floor
charges increased by 5% over the study period. It is impos-
sible to adjust for all potential increases in charges; there-
fore, the 23% increase seen in the TXA group needs to be
considered in light of this limitation. The relatively short
follow-up period is another limitation, inasmuch as several
adult studies have demonstrated that detecting adverse out-
comes with aprotinin requires longer observation. However,
it has also been suggested that the aprotinin-treated patients
were sicker.17 Despite being one of the largest neonatal
trials, the sample size was small and may have been insuf-
ficiently powered to detected small but significant differ-
ences in other clinical outcomes.
CONCLUSIONS
In conclusion, aprotinin, compared with TXA, was asso-
ciated with reduced perioperative blood product use, im-
proved early indices of postoperative recovery, and
attenuated some indices of cytokine activation, without ap-
parent adverse effects. These findings provide evidence that
aprotinin may have beneficial effects in the context of neo-
natal cardiac surgery. Taken together, past and present stud-
ies suggest that a randomized prospective trial of aprotinin
in pediatric cardiac patients is warranted and has the poten-
tial to be associated with a favorable risk-benefit ratio. Even
if a prospective study of aprotinin in the pediatric popula-
tion is not undertaken, further studies of the currently avail-
able antifibrinolytics are warranted. The adverse outcomes
in adults that ultimately resulted in the discontinuation of
aprotinin may be due to preoperative comorbidities (eg, ath-
erosclerosis, diabetes, renal insufficiency) and related path-
ophysiologic processes that are present to a far greater
extent in adult patients. For example, in such patients,
aprotinin-mediated inhibition of the kinin and kallikrein
pathways may suppress endogenous renal protective mech-
anisms and accentuate the renal injury incurred by CPB and
cardiac surgery, but this issue remains speculative and war-
rants further study.
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